Primary Sclerosing Cholangitis and Cholangiocarcinoma

ABSTRACT

Primary sclerosing cholangitis (PSC), a cholestatic liver disease characterized by fibrosing inflammatory damage of the biliary tree, is a risk factor for cholangiocarcinoma (CCA). Indeed, the prevalence of CCA in patients with PSC ranges from 7 to 13%. The major challenges of CCA in PSC patients relate to lack of methods for early diagnosis and the absence of effective treatment. Early diagnosis of CCA in PSC is delayed because its clinical presentation can mimic benign dominant biliary strictures. Moreover, biliary and serum tests to diagnose development of CCA in PSC are limiting, although the use of advanced cytologic techniques for aneuploidy and chromosomal aberrations are promising in this regard. As a result, current therapies do not extend survival with the exception of protocol liver transplantation available to a selected group of patients. Future studies should emphasize deciphering the sequence of events that transform the inflammatory changes of the biliary tree to cancer. Only then will chemoprevention, early diagnosis, and therapy of CCA in patients with PSC improve.

KEYWORDS

Bile duct cancer - inflammation - malignant transformation - primary sclerosing cholangitis

REFERENCES

• 1 Gores G J. Cholangiocarcinoma: current concepts and insights.  Gastroenterology. 2003;  125 1536-1538
• 2 Khan S A, Davidson B R, Goldin R et al.. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document.  Gut. 2002;  51(suppl 6) VI1-VI9
• 3 Helzberg J H, Peterson J M, Boyer J L. Improved survival with primary sclerosing cholangitis. A review of the clinicopathologic features and comparison of symptomatic and asymptomatic patients.  Gastroenterology. 1987;  92 1869-1875
• 4 Miros M, Kerlin P, Walker N et al.. Predicting cholangiocarcinoma in patients with primary sclerosing cholangitis before transplantation.  Gut. 1991;  32 1369-1373
• 5 Burak K, Angulo P, Pasha T M et al.. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis.  Am J Gastroenterol. 2004;  99 523-526
• 6 Farrant J M, Hayllar K M, Wilkinson M L et al.. Natural history and prognostic variables in primary sclerosing cholangitis.  Gastroenterology. 1991;  100 1710-1717
• 7 Bergquist A, Ekbom A, Olsson R et al.. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis.  J Hepatol. 2002;  36 321-327
• 8 Broome U, Olsson R, Loof L et al.. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis.  Gut. 1996;  38 610-615
• 9 Broome U, Lofberg R, Veress B, Eriksson L S. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential.  Hepatology. 1995;  22 1404-1408
• 10 Rosen C B, Nagorney D M. Cholangiocarcinoma complicating primary sclerosing cholangitis.  Semin Liver Dis. 1991;  11 26-30
• 11 Chalasani N, Baluyut A, Ismail A et al.. Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study.  Hepatology. 2000;  31 7-11
• 12 Rizzi P M, Ryder S D, Portmann B et al.. p53 Protein overexpression in cholangiocarcinoma arising in primary sclerosing cholangitis.  Gut. 1996;  38 265-268
• 13 Boberg K M, Schrumpf E, Bergquist A et al.. Cholangiocarcinoma in primary sclerosing cholangitis: K-ras mutations and p53 dysfunction are implicated in the neoplastic development.  J Hepatol. 2000;  32 374-380
• 14 Bergquist A, Glaumann H, Stal P, Wang G S, Broome U. Biliary dysplasia, cell proliferation and nuclear DNA-fragmentation in primary sclerosing cholangitis with and without cholangiocarcinoma.  J Intern Med. 2001;  249 69-75
• 15 Kubicka S, Kuhnel F, Flemming P et al.. K-ras mutations in the bile of patients with primary sclerosing cholangitis.  Gut. 2001;  48 403-408
• 16 Jaiswal M, LaRusso N F, Burgart L J, Gores G J. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism.  Cancer Res. 2000;  60 184-190
• 17 Jaiswal M, LaRusso N F, Shapiro R A, Billiar T R, Gores G J. Nitric oxide-mediated inhibition of DNA repair potentiates oxidative DNA damage in cholangiocytes.  Gastroenterology. 2001;  120 190-199
• 18 Ishimura N, Bronk S F, Gores G J. Inducible nitric oxide synthase up-regulates Notch-1 in mouse cholangiocytes: implications for carcinogenesis.  Gastroenterology. 2005;  128 1354-1368
• 19 Taniai M, Higuchi H, Burgart L J, Gores G J. p16INK4a promoter mutations are frequent in primary sclerosing cholangitis (PSC) and PSC-associated cholangiocarcinoma.  Gastroenterology. 2002;  123 1090-1098
• 20 Ishimura N, Bronk S F, Gores G J. Inducible nitric oxide synthase upregulates cyclooxygenase-2 in mouse cholangiocytes promoting cell growth.  Am J Physiol Gastrointest Liver Physiol. 2004;  287 G88-G95
• 21 Hirohashi K, Uenishi T, Kubo S et al.. Macroscopic types of intrahepatic cholangiocarcinoma: clinicopathologic features and surgical outcomes.  Hepatogastroenterology. 2002;  49 326-329
• 22 Bergquist A, Glaumann H, Persson B, Broome U. Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case-control study.  Hepatology. 1998;  27 311-316
• 23 Hadjis N S, Collier N A, Blumgart L H. Malignant masquerade at the hilum of the liver.  Br J Surg. 1985;  72 659-661
• 24 Nichols J C, Gores G J, LaRusso N F et al.. Diagnostic role of serum CA 19-9 for cholangiocarcinoma in patients with primary sclerosing cholangitis.  Mayo Clin Proc. 1993;  68 874-879
• 25 Levy C, Lymp J, Angulo P et al.. The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis.  Dig Dis Sci. 2005;  50 1734-1740
• 26 Magnani J L, Steplewski Z, Koprowski H, Ginsburg V. Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin.  Cancer Res. 1983;  43 5489-5492
• 27 Vestergaard E M, Hein H O, Meyer H et al.. Reference values and biological variation for tumor marker CA 19-9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population.  Clin Chem. 1999;  45 54-61
• 28 Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen.  Am J Gastroenterol. 1990;  85 350-355
• 29 Manfredi R, Barbaro B, Masselli G, Vecchioli A, Marano P. Magnetic resonance imaging of cholangiocarcinoma.  Semin Liver Dis. 2004;  24 155-164
• 30 Hadjis N S, Adam A, Gibson R et al.. Nonoperative approach to hilar cancer determined by the atrophy-hypertrophy complex.  Am J Surg. 1989;  157 395-399
• 31 Keiding S, Hansen S B, Rasmussen H H et al.. Detection of cholangiocarcinoma in primary sclerosing cholangitis by positron emission tomography.  Hepatology. 1998;  28 700-706
• 32 Fevery J, Buchel O, Nevens F et al.. Positron emission tomography is not a reliable method for the early diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis.  J Hepatol. 2005;  43 358-360
• 33 Eloubeidi M A, Chen V K, Jhala N C et al.. Endoscopic ultrasound-guided fine needle aspiration biopsy of suspected cholangiocarcinoma.  Clin Gastroenterol Hepatol. 2004;  2 209-213
• 34 Rumalla A, Baron T H, Leontovich O et al.. Improved diagnostic yield of endoscopic biliary brush cytology by digital image analysis.  Mayo Clin Proc. 2001;  76 29-33
• 35 Baron T H, Harewood G C, Rumalla A et al.. A prospective comparison of digital image analysis and routine cytology for the identification of malignancy in biliary tract strictures.  Clin Gastroenterol Hepatol. 2004;  2 214-219
• 36 Kipp B R, Stadheim L M, Halling S A et al.. A comparison of routine cytology and fluorescence in situ hybridization for the detection of malignant bile duct strictures.  Am J Gastroenterol. 2004;  99 1675-1681
• 37 Pichlmayr R, Weimann A, Ringe B. Indications for liver transplantation in hepatobiliary malignancy.  Hepatology. 1994;  20 33S-40S
• 38 Iwatsuki S, Todo S, Marsh J W et al.. Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation.  J Am Coll Surg. 1998;  187 358-364
• 39 Jeyarajah D R, Netto G J, Lee S P et al.. Recurrent primary sclerosing cholangitis after orthotopic liver transplantation: is chronic rejection part of the disease process?.  Transplantation. 1998;  66 1300-1306
• 40 Loinaz C, Abradelo M, Gomez R et al.. Liver transplantation and incidental primary liver tumors.  Transplant Proc. 1998;  30 3301-3302
• 41 Bokemeyer C, Kollmannsberger C, Oettle H, Kanz L. Current aspects of chemotherapy of metastatic pancreatic and biliary tract carcinomas [in German].  Schweiz Rundsch Med Prax. 2000;  89 1545-1552
• 42 Jonas S, Kling N, Guckelberger O et al.. Orthotopic liver transplantation after extended bile duct resection as treatment of hilar cholangiocarcinoma. First long-term results.  Transpl Int. 1998;  11(suppl 1) S206-S208
• 43 Shimoda M, Farmer D G, Colquhoun S D et al.. Liver transplantation for cholangiocellular carcinoma: analysis of a single-center experience and review of the literature.  Liver Transpl. 2001;  7 1023-1033
• 44 Foo M L, Gunderson L L, Bender C E, Buskirk S J. External radiation therapy and transcatheter iridium in the treatment of extrahepatic bile duct carcinoma.  Int J Radiat Oncol Biol Phys. 1997;  39 929-935
• 45 Rea D J, Heimbach J K, Rosen C B et al.. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma.  Ann Surg. 2005;  242 451-458 , [discussion 458-461]
• 46 Sudan D, DeRoover A, Chinnakotla S et al.. Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma.  Am J Transplant. 2002;  2 774-779
• 47 Levy M J, Baron T H, Gostout C J, Petersen B T, Farnell M B. Palliation of malignant extrahepatic biliary obstruction with plastic versus expandable metal stents: an evidence-based approach.  Clin Gastroenterol Hepatol. 2004;  2 273-285
• 48 De Palma G D, Pezzullo A, Rega M et al.. Unilateral placement of metallic stents for malignant hilar obstruction: a prospective study.  Gastrointest Endosc. 2003;  58 50-53
• 49 Hintze R E, Abou-Rebyeh H, Adler A et al.. Magnetic resonance cholangiopancreatography-guided unilateral endoscopic stent placement for Klatskin tumors.  Gastrointest Endosc. 2001;  53 40-46
• 50 Rumalla A, Baron T H, Wang K K et al.. Endoscopic application of photodynamic therapy for cholangiocarcinoma.  Gastrointest Endosc. 2001;  53 500-504
• 51 Ortner M, Caca K, Berr F et al.. Successful photodynamic therapy for nonresectable cholangiocarinoma: a randomized prospective study.  Gastroenterology. 2003;  125 1355-1363
• 52 Gores G J. A spotlight on cholangiocarcinoma.  Gastroenterology. 2003;  125 1536-1538